This 1999 study evaluated the safety of estrogen replacement therapy (ERT) in 76 women with a history of breast cancer, including 50 who used ERT for up to 32 years. The findings indicated that ERT did not increase the risk of cancer recurrence or mortality. Additionally, the addition of progestogens
This observational study examined 103 women who recently completed early-stage breast cancer treatment, finding that over 60% experienced fatigue and sleep disturbances, and 25% showed elevated depressive symptoms. Chemotherapy was associated with higher levels of fatigue, sleep problems, depressive symptoms, and increased levels of the inflammatory marker sTNF-RII (all P
A review published in Oncology Nursing Forum examined the controversy surrounding hormone replacement therapy (HRT) in breast cancer survivors, focusing on its risks, benefits, and long-term health outcomes. While HRT has been associated with improved quality of life, reduced risks of cardiovascular disease, and osteoporosis prevention in postmenopausal women, its
This study examines physicians’ perspectives on initiating hormone replacement therapy (HRT) in breast cancer survivors, highlighting the complexities involved in balancing the risks and benefits of treatment for managing menopausal symptoms. Given concerns about HRT potentially increasing the risk of cancer recurrence, the study explores the decision-making process of healthcare
This cohort study, published in Obstetrics & Gynecology (2023), evaluated the safety of vaginal estrogen therapy (VET) for treating genitourinary syndrome of menopause (GSM) in women with a history of breast cancer. Analyzing data from 42,113 women diagnosed with GSM after breast cancer treatment, with 5.0% receiving VET, the study
This study assessed the quality of life (QOL) in breast cancer survivors, comparing those who underwent hormone replacement therapy (HRT) with those who did not. The findings indicated no significant differences in QOL between the two groups across social, physical, psychological, and spiritual domains. Most participants showed recovery to near-normal
This randomized controlled trial assessed the safety and efficacy of estrogen-replacement therapy (ERT) in women with a history of breast cancer. The study found no increased risk of breast cancer recurrence in women receiving ERT, and there were no significant differences in overall survival rates between the ERT and placebo
This systematic review and meta-analysis examined the safety and serum estradiol levels associated with hormonal treatments for vulvovaginal atrophy (VVA) in breast cancer survivors. The findings indicate that certain hormonal therapies lead to minimal increases in serum estradiol levels, remaining within safe thresholds, and effectively alleviating VVA symptoms such as
This review addresses the management of menopausal symptoms in breast cancer survivors, focusing on the challenges of treating symptoms such as hot flashes, vaginal dryness, and osteoporosis without the use of traditional hormone replacement therapy (HRT), which is contraindicated due to its association with increased breast cancer recurrence. The article
This study examined the prevalence and severity of menopausal symptoms in breast cancer survivors, finding that nearly all participants reported vasomotor symptoms, with hot flashes being the most common. The severity of symptoms negatively impacted the women’s perceived quality of life, as well as their partners’. Despite the widespread issue,
